Renal cell carcinoma metastatic to the stomach: single‐centre experience and literature review

Pollheimer, Marion J.; Hinterleitner, Thomas; Pollheimer, Verena S.; Schlemmer, Andrea; Langner, Cord

doi:10.1111/j.1464-410x.2008.07617.x

Cited by 60 publications

(61 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RCC is known to cause metastatic recurrences a number of years after its resection and even after immunotherapy or molecularly targeted therapy. Whereas the gastrointestinal tract is a rare site for metastases of RCC, rare sites of metastasis, including the thyroid, pancreas, skeletal muscles and skin, are characteristic of RCC (5,6).…”

Section: Introductionmentioning

confidence: 99%

“…The breast, melanoma, lung and esophagus are the most common primary sites of metastases to the stomach (2)(3)(4). The most common sites of metastasis in renal cell carcinoma (RCC), which accounts for 2 to 3% of adult malignant neoplasms, are the lung (75%), lymph nodes (36%), bone (20%) and liver (18%) (5). RCC is known to cause metastatic recurrences a number of years after its resection and even after immunotherapy or molecularly targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metastatic gastric tumors arising from renal cell carcinoma: Clinical characteristics and outcomes of this uncommon disease

et al. 2012

View full text Add to dashboard Cite

Abstract. We analyzed the clinicopathological characteristics and therapeutic outcomes of patients with metastatic gastric tumors arising from renal cell carcinoma (RCC) to identify post-therapy prognostic factors. A total of 22 patients who were treated for metastatic gastric tumors arising from RCC were included in the study. A retrospective review was performed on the clinical characteristics of this disease. The median time interval from radical excision of the primary tumor to the detection of gastric metastasis (IGM) was 6.3 years. The overall 1-and 3-year survival rates were 52.6 and 21.0%, respectively, and the median survival time was 19 months. Compared with patients with an IGM of <6.3 years, patients with an IGM of ≥6.3 years showed a significantly longer median survival time (5 vs. 24 months; P=0.017). The median tumor size was significantly greater in patients with multiple metastases compared with those with solitary metastasis (4 vs. 2 cm; P=0.036). The incidence of patients who had undergone therapeutic tumor resection was significantly higher in patients with solitary metastasis compared with those with multiple metastases (100.0 vs. 35.7%; P=0.019). The appearance of gastric tumors in patients with a history of RCC should prompt the clinician to investigate the possibility of metastasis even several years after detection of the original renal cancer. A longer interval from nephrectomy to the diagnosis of gastric metastasis is generally indicative of a better prognosis, most likely the result of less aggressive tumor growth.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Metastatic gastric tumors arising from renal cell carcinoma: Clinical characteristics and outcomes of this uncommon disease

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The treatment of gastric metastases is controversial. The patients have poor prognosis with frequent extragastric metastases, and the treatment is endoscopic therapy and arterial embolization (7,8). The absence of evidence for other metastases and the presence of large tumor did not support the consideration of therapeutic endoscopy.…”

Section: Discussionmentioning

confidence: 99%

Gastric metastasis from renal cancer six years after nephrectomy

Cruz

Ramírez²,

Sánchez

et al. 2011

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Renal cell carcinoma is the third most common urogenital neoplasia (1). The lung and bone tissues represent the most frequent metastatic sites of renal cell carcinoma (2). Metastases in the stomach are rare and have been essentially described during autopsies (3). In this paper, we present a case of large metastatic gastric tumor whose origin was a renal cell carcinoma treated years ago. Case reportA 56 year old woman was diagnosed with stage one renal adenocarcinoma 6 years ago. She was treated with right radical nephrectomy and adjuvant chemotherapy. Three years later was diagnosed and treated of brain metastasis located in the frontal lobe, as well as in lung. A year ago, she came to our hospital for upper gastrointestinal bleeding. She presented acceptable general condition and nutritional, blood pressure 120/70 mmHg and normal cardio-respiratory auscultation. The abdomen was soft, non-tender, and no masses or organ enlargements. The analytical study revealed 6.3 g/dl hemoglobin. A thoracic abdominal TAC showed a large mass in the body and antrum stomach of 11 cm diameter without invasion adjacent structures. An upper gastrointestinal endoscopy revealed a large neoplasm from body to gastric antrum with mamelonated aspect. The patient underwent subtotal gastrectomy. The postoperative course was uneventful. The pathology and immunohistochemical study showed metastasis of kidney carcinoma ( Fig. 1). DiscussionMetastatic gastric cancer is uncommon. The most frequent location sites of cancer cells are in the body and gastric fundus, and single tumors predominate against multiple. Although generally gastric metastases account for 0.2-0.7% of stomach tumors, the metastatic tumor from carcinoma renal cells is extremely rare (3) and is an event late. The gastric metastases from renal cell carcinoma are diagnosed years after the primary tumor (4). The histological diagnoses require immunohistochemical analysis for differential diagnostic. We studied AE1/AE3 and vimentin markers, and the most recent CD10 and renal cell carcinoma markers (RCC-Ma). CD10 is a cell surface enzyme expressed in several types of normal cells including the brush border of renal tubular epithelial cells. Positivity for this marker is seen in more than 90% of renal clear carcinomas (5). RCC-Ma is a monoclonal antibody against a normal renal proximal tubule antigen. RCCMa expression is relatively specific for primary clear cell in renal carcinoma (6). In our case, the markers confirmed the diagnosis of renal carcinoma. The classic vimentin and AE1/AE3 markers were strongly positive, while CD10 and RCC-Ma showed moderately and weakly positive staining, respectively. The treatment of gastric metastases is controversial. The patients have poor prognosis with frequent extragastric metastases, and the treatment is endoscopic therapy and arterial embolization (7,8). The absence of evidence for other metastases and the presence of large tumor did not support the consideration of therapeutic endoscopy. By contrast, subtotal gastrectomy allowed acceptable...

show abstract

“…The mean age of presentation was 65 years for males and 68 years for females (3). Gastric metastasis from renal cell carcinoma often starts as a submucosal lesion, which encroaches onto the mucosa and becomes ulcerated.…”

Section: Discussionmentioning

confidence: 99%